Downloads: 0 | Views: 157

Informative Article | Pharmacotherapeutics | India | Volume 11 Issue 6, June 2022 | Popularity: 4.1 / 10

Rate This Article!      

Will Dostarlimab Become the New Rectal Cancer Drug of Choice?

Motupalli Sankeerth Kumar, Ponnaluri Lalitha, Seelam Victor John Wilson

Abstract: Information on a recent clinical trial in the United States on a drug that has been shown to be nearly 100% effective against rectal cancer in the sample population.

Keywords: Dostarlimab, Rectal cancer, new drug of choice

Edition: Volume 11 Issue 6, June 2022

Pages: 1369 - 1369

Make Sure to Disable the Pop-Up Blocker of Web Browser

Click to Cite this Article